TORC resTORbio, Inc.

1.10-6.85 (-86.16%)
IEX price: 3:59:49 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$6.21-$14.05
Volume
26,215,262
Avg Volume
223,484
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$40.09M
Enterprise Value (EV)
$181.70M
PE Ratio
-
EV/EBITDA
-4.59
Price/Sales
-
Price/Book
2.78
PEG Ratio
0.04

Financials

Revenue
-
Gross Profit
-$80.00K
EBITDA
-$39.62M
EPS, ttm
-$1.78
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
3/26/2020 (132 days)
Debt to Equity
-
Debt
$249.64M
Cash
$108.03M
Net Debt
$141.61M

Performance

Beta
1.77
200 Day Moving Avg
$8.59
50 Day Moving Avg
$8.30
52 Week Change
-37.45%
YTD Change
-96.84%
1 Month Change
15.05%
3 Month Change
-19.29%
6 Month Change
0.25%
1 Year Change
-37.45%
2 Year Change
-47.00%
5 Year Change
-47.00%

Share Count

Shares Outstanding
36.4M
Float
20.7M
Restricted Shares
15.7M
Restricted Shares, %
43.07%

resTORbio, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Chen Schor

Website: http://www.restorbio.com

Description: resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Employees: 21